A-317920 | CAS#360551-59-3 | H3 Inverse Agonist Radioligand

MedKoo Cat#: 531350 | Name: A-317920

Description:

WARNING: This product is for research use only, not for human or veterinary use.

A-317920 is an inverse agonist radioligand.

Chemical Structure

A-317920

CAS#360551-59-3

Theoretical Analysis

MedKoo Cat#: 531350

Name: A-317920

CAS#: 360551-59-3

Chemical Formula: C25H31N3O5

Exact Mass: 453.2264

Molecular Weight: 453.54

Elemental Analysis: C, 66.21; H, 6.89; N, 9.27; O, 17.64

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

A-317920

IUPAC/Chemical Name

N-[(2R)-1-[4-[3-[4-(cyclopropanecarbonyl)phenoxy]propyl]piperazin-1-yl]-1-oxopropan-2-yl]furan-2-carboxamide

InChi Key

RTRADBQSZJIRMT-GOSISDBHSA-N

InChi Code

InChI=1S/C25H31N3O5/c1-18(26-24(30)22-4-2-16-33-22)25(31)28-14-12-27(13-15-28)11-3-17-32-21-9-7-20(8-10-21)23(29)19-5-6-19/h2,4,7-10,16,18-19H,3,5-6,11-15,17H2,1H3,(H,26,30)/t18-/m1/s1

SMILES Code

O=C(C1=CC=CO1)N[C@H](C)C(N2CCN(CCCOC3=CC=C(C(C4CC4)=O)C=C3)CC2)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 453.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Yao BB, Witte DG, Miller TR, Carr TL, Kang CH, Cassar S, Faghih R, Bennani YL, Surber BW, Hancock AA, Esbenshade TA. Use of an inverse agonist radioligand [3H]A-317920 reveals distinct pharmacological profiles of the rat histamine H3 receptor. Neuropharmacology. 2006 Mar;50(4):468-78. PubMed PMID: 16316670. 2: Esbenshade TA, Yao BB, Witte DG, Carr TL, Sharma R, Baranowski JL, Krueger KM, Miller TR, Surber BW, Faghih R, Hancock AA. Use of novel, non-imidazole inverse agonist radioligands to define histamine H3 receptor pharmacology. Inflamm Res. 2005 Apr;54 Suppl 1:S46-7. PubMed PMID: 15928830. 3: Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE, Buckley MJ, Ballard ME, Komater VA, Miner H, Zhang M, Faghih R, Rueter LE, Bitner RS, Drescher KU, Wetter J, Marsh K, Lemaire M, Porsolt RD, Bennani YL, Sullivan JP, Cowart MD, Decker MW, Hancock AA. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther. 2005 Apr;313(1):176-90. PubMed PMID: 15608077. 4: Yao BB, Witte DG, Miller TR, Krueger KM, Carr TL, Kang CH, Faghih R, Bennani YL, Esbenshade TA, Hancock AA. In vitro pharmacological properties of two novel non-imidazole H3 receptor (H3R) antagonists. Inflamm Res. 2003 Apr;52 Suppl 1:S45-6. PubMed PMID: 12755405. 5: Fox GB, Pan JB, Faghih R, Esbenshade TA, Lewis A, Bitner RS, Black LA, Bennani YL, Decker MW, Hancock AA. Identification of novel H3 receptor (H3R) antagonists with cognition enhancing properties in rats. Inflamm Res. 2003 Apr;52 Suppl 1:S31-2. PubMed PMID: 12755398. 6: Esbenshade TA, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Fox GB, Faghih R, Bennani YL, Williams M, Hancock AA. Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects. J Pharmacol Exp Ther. 2003 Jun;305(3):887-96. PubMed PMID: 12606603. 7: Fox GB, Pan JB, Radek RJ, Lewis AM, Bitner RS, Esbenshade TA, Faghih R, Bennani YL, Williams M, Yao BB, Decker MW, Hancock AA. Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. J Pharmacol Exp Ther. 2003 Jun;305(3):897-908. PubMed PMID: 12606600.